To add to the previous post on pharmacogenomics, here’s another aspect of the coming ability to get more and more specific information about cancer characteristics. Not only will there be more "personalization" of cancer treatment based on new depth,  but it’s going to yield yet more complications in drug development and pricing. But as we move into the world where ...

This article in the NYTimes about genetic testing that differentiates the risk of recurrence for women with breast cancer and, therefore, affects treatment decisions in some cases is a harbinger of things to come. The thing is that this is just one instance of a whole new dimension in using genetic testing at various phases of cancer diagnosis and treatment. ...

I didn’t know you could freeze your butt off in Palm Springs this time of year. You can. Unseasonably rainy and frigid weather was a sidelight to the BioAgenda Summit I attended earlier this week with the CA Div past-president and with Julia DeFehr, distinguished giving staff. The thing that’s worth talking about is that—as a direct consequence I’ve been ...

I’ll refrain from reading too much into this, but the sale of IBM’s PC business to a Chinese company is one of those sign-of-the-times things. The transaction…points to the rising global aspirations of corporate China as it strives to become a trusted supplier to Western companies and consumers. The sale also signals a recognition by I.B.M., the prototypical American multinational, ...